tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ionis Pharmaceuticals: Advancements and Catalysts Drive Buy Rating
PremiumRatingsIonis Pharmaceuticals: Advancements and Catalysts Drive Buy Rating
18d ago
Promising Outlook for Ionis Pharmaceuticals: Buy Rating Backed by Pipeline Advancements and Strategic Focus
Premium
Ratings
Promising Outlook for Ionis Pharmaceuticals: Buy Rating Backed by Pipeline Advancements and Strategic Focus
18d ago
Ionis Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
Premium
The Fly
Ionis Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
18d ago
CarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
PremiumThe FlyCarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
30d ago
Ionis Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
Premium
The Fly
Ionis Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
30d ago
Ionis Pharmaceuticals price target raised to $80 from $78 at Barclays
Premium
The Fly
Ionis Pharmaceuticals price target raised to $80 from $78 at Barclays
1M ago
Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease
PremiumRatingsBuy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease
1M ago
Morning Movers: Metsera surges, Pfizer gains after acquisition pact
Premium
The Fly
Morning Movers: Metsera surges, Pfizer gains after acquisition pact
1M ago
Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond James
Premium
The Fly
Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond James
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100